Zai Lab is an innovative, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing transformative products that address medical conditions with significant unmet patient needs in the areas of oncology, autoimmune disorders, infectious diseases and neurological disorders. Our goal is to leverage our capabilities and resources to reach one million patients by 2030, positively impacting human health worldwide.
We're tracking Zai Lab's market expansion
New Product & Tech activity — 2 fresh signals just appeared.
How Zai Lab's international expansion compares to its competitors
Zai LabYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Zai LabYou | 0 | 0 | — | 0 | 0 |
Principle Scientist, Antibody Discovery Protein Engineering
View postingShanghai, China · 4w ago
Clinical QC Manager- Hybrid
View postingCambridge, MA · last mo.
Clinical QC Manager- Hybrid
View postingSouth San Francisco, CA · last mo.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Zai Lab reports Q2 2025 revenue of $110M, up 9% YoY. Reaffirms 2025 revenue guidance of $560-590M. Operating loss narrows 28% YoY.
Zai Lab's zocilurtatug shows strong efficacy in SCLC patients, with 68% ORR in second-line treatment. Global Phase 3 trial initiated for SCLC.
Zai Lab's zocilurtatug pelitecan shows strong efficacy in heavily pretreated ES-SCLC patients, with 68% ORR in second-line treatment at 1.6mg/kg dose. Global Phase 3 trial initiated.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Zai Lab's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
